We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00962429
First Posted: August 20, 2009
Last Update Posted: January 31, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Collins Medical Trust
Information provided by (Responsible Party):
Jau-Shin Lou, Oregon Health and Science University
  Purpose
The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).

Condition Intervention Phase
CIDP Chronic Inflammatory Demyelinating Polyneuropathy Drug: lipoic acid Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study

Resource links provided by NLM:


Further study details as provided by Jau-Shin Lou, Oregon Health and Science University:

Primary Outcome Measures:
  • Muscle strength [ Time Frame: 16 weeks ]

Secondary Outcome Measures:
  • Hughes Functional Disability Scale [ Time Frame: 16 weeks ]
  • Forced vital capacity (FVC) [ Time Frame: 16 weeks ]
  • Motor nerve conduction studies (NCS) [ Time Frame: 16 weeks ]

Enrollment: 8
Study Start Date: February 2009
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Lipoic acid
alpha lipoic acid
Drug: lipoic acid
Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Other Name: LA
Placebo Comparator: Placebo
sugar pill
Drug: lipoic acid
Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Other Name: LA

Detailed Description:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a progressive disease leading to paralysis. CIDP is an immune-mediated disorder resulting from a synergistic interaction of T cell-mediated and B cell-mediated immune responses directed against peripheral nerve antigens. These immune mediated responses in turn increase the production of reactive oxygen intermediate and cause oxidative damage of the peripheral nerve system. Although corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg) reduce impairment caused by CIDP at least temporarily and can be used as a first-line treatments, they are not ideal for long-term treatment because of serious side effects and cost. Alpha lipoic acid (LA) is an antioxidant that also possesses anti-immune activity. It is effective in treating diabetic neuropathy. It is also promising in treating patients with multiple sclerosis.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of CIDP
  • on a stable dose of immunotherapy for at least 3 months before enrolling in the study

Exclusion Criteria:

  • myelopathy or evidence of central demyelination
  • persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or familial neuropathy)
  • evidence of systemic disease that might cause neuropathy
  • heart diseases (congestive heart failure or arrhythmia)
  • pulmonary conditions (asthma or CIPD)
  • rheumatoid conditions (such as rheumatoid arthritis)
  • renal failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00962429


Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
Collins Medical Trust
Investigators
Principal Investigator: Jau-Shin Lou, MD, PhD Oregon Health and Science University
  More Information

Responsible Party: Jau-Shin Lou, Associate Professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT00962429     History of Changes
Other Study ID Numbers: CMT-Lou
First Submitted: August 19, 2009
First Posted: August 20, 2009
Last Update Posted: January 31, 2013
Last Verified: January 2013

Keywords provided by Jau-Shin Lou, Oregon Health and Science University:
neuropathy, lipoic acid

Additional relevant MeSH terms:
Polyneuropathies
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Polyradiculoneuropathy
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Thioctic Acid
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances